No abstract available.
Drug Therapy* ; Hypertension*

Humans ; Hypertension ; therapy

Clinical guideline for treatment of pulmonary arterial hypertension (PAH) has been changing during the past 10 years with development of targeted therapy for PAH. Treatment of PAH should include general measures and supportive care, treatment of associated disease, targeted treatment for PAH, and lung transplantation in advanced cases. Targeted therapy for PAH can improve symptom, quality of life and time to clinical worsening in PAH patients. Regular follow-up to evaluate the treatment efficacy is essential and insufficient treatment efficacy should be modified with other class of medication or preparing lung transplantations. Research for new medication is actively performed and novel drug is expected to be improving survival of PAH patients.
Humans ; Hypertension, Pulmonary ; therapy

No abstract available.
Humans ; *Hypertension, Portal/diagnosis/therapy

The results of treatment of high blood presure in pregnant intoxication on 61 pregnant women are as follows: success rate 54/61 (88.52%). Systolic blood pressure and diastolic blood pressure decreased significantly in comparing with the use of Aldomet in combining with Hydralazin (p < 0.05). No sign of liver and kidney failures were reported, no increase of serum glucose and serum cholesterol, blood creatinine decreased nonsignificantly (p > 0.05), uremia decreased significantly. For the fetus, Apgar index was tolerable, no sign of monster and stillbirth. Conclusion: Amlodipin is good drug for treating high blood pressure in pregnant intoxication.
Therapy ; Amlodipine ; Pregnant Women ; Hypertension

This short review illustrates current epidemiology, diagnosis and treatment of pulmonary hypertension. In the first part, classification, definition and prevalence of pulmonary hypertension (PH) are explained. According to recent reports, overall PH prevalence was 0.3% to 6.0% with left heart disease occupying the most proportion, followed by pulmonary disease, pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) constituting far less proportion of 10 to 50 per 1 million people. In diagnosis, flow of diagnosis of PH, differential diagnosis of PH and how to determine the severity of PH are explained including recent development of magnetic resonance imaging (MRI) and gene abnormality study on BMPRII. In treatment, newly-developed pulmonary vasodilators are shown as well as how to combine them in PAH, and in CTEPH treatment the drugs, operation and catheter therapy including our experience are demonstrated.
Humans ; Hypertension, Pulmonary ; diagnosis ; therapy

Humans ; Hypertension, Pulmonary ; diagnosis ; therapy

Humans ; Child ; Hypertension, Pulmonary/therapy*

Humans ; Hyperaldosteronism/therapy* ; Aldosterone ; Hypertension

Humans ; China/epidemiology* ; Hypertension/therapy*